Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial-Reference-Cited by-同舟云学术

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

Published:2019-06 Issue: Volume:114 Page:107-116
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Morris Michael J.,Loriot Yohann,Sweeney Christopher J.,Fizazi Karim,Ryan Charles J.,Shevrin Daniel H.,Antonarakis Emmanuel S.,Pandit-Taskar Neeta,Deandreis Désirée,Jacene Heather A.,Vesselle Hubert,Petrenciuc Oana,Lu Cindy,Carrasquillo Jorge A.,Higano Celestia S.

Funder

Bayer

Bayer Healthcare

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?;Bruland;Clin Cancer Res,2006

2. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice;Henriksen;J Nucl Med,2003

3. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models;Suominen;Clin Cancer Res,2017

4. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis;Suominen;J Natl Cancer Inst,2013

5. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Theranostics: Pharmaceutical View;Pharmaceutical Science;2024-08-21

2. Quantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy;Cancer Urology;2024-08-15

3. Targeted Radiopharmaceutical Therapy for Bone Metastases;Seminars in Nuclear Medicine;2024-07

4. Combination Strategies and Targeted Radionuclide Therapies;Seminars in Nuclear Medicine;2024-07

5. Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE);Cancer;2024-02-10